Live Analyst Rating Changes 19209 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mathew Blackman
TD

Mathew Blackman

TD Cowen
Wall Street Analyst
★★★☆☆
#1450
on 13Foresight · ranked by our own returns
56%
Success Rate
+2.9%
Average Return
19 of 34 calls profitable · -4.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 56% of Mathew Blackman's ratings turned a profit when each position was held for 1 year — averaging +2.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

34 Buy 18 Hold 0 Sell
Mathew's Stock Coverage 18 ratings · 2026-08-07
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PODD
Insulet
 Aug 06, 2026 HOLD Strong Buy
+61.2% avg upside
32 analysts
$144.00
3.32% Upside
 +0.0% ·
ZBH
Zimmer Biomet Holdings
 Aug 05, 2026 BUY Buy
+16.2% avg upside
38 analysts
$115.00
18.31% Upside
 -1.0% ·
OFIX
Orthofix Medical
 Aug 05, 2026 HOLD Buy
+173.2% avg upside
15 analysts
$12.00
13.29% Upside
 · ·
ATEC
Alphatec Holdings
 Aug 05, 2026 BUY Strong Buy
+80.0% avg upside
23 analysts
$13.00
41.25% Upside
 -5.4% ·
KIDS
OrthoPediatrics
 Aug 04, 2026 BUY Strong Buy
+36.4% avg upside
10 analysts
$23.00
0.72% Upside
 +9.3% ·
SIBN
SI-Bone
 Aug 04, 2026 BUY Strong Buy
+43.4% avg upside
18 analysts
$20.00
10.31% Upside
 +0.0% ·
ISRG
Intuitive Surgical
 Aug 03, 2026 BUY Strong Buy
+28.2% avg upside
36 analysts
$485.00
29.70% Upside
 -0.4% ·
SYK
Stryker
 Jul 31, 2026 HOLD Strong Buy
+9.2% avg upside
37 analysts
$355.00
5.21% Upside
 +3.1% ·
GMED
Globus Medical
 Jun 22, 2026 BUY Strong Buy
+14.6% avg upside
24 analysts
$115.00
41.82% Upside
 +2.4% ·
TNDM
Tandem Diabetes Care
 May 08, 2026 BUY Buy
+72.2% avg upside
29 analysts
$28.00
49.09% Upside
 +25.7% ·
BBNX
Beta Bionics, Inc.
 Apr 21, 2026 HOLD Strong Buy
+52.4% avg upside
13 analysts
$16.00
13.47% Upside
 +4.6% ·
CLPT
ClearPoint Neuro
 May 14, 2025 BUY Strong Buy
+66.2% avg upside
7 analysts
$25.00
86.68% Upside
 +2.7% ·
INGN
Inogen
 May 08, 2025 HOLD Buy
+279.6% avg upside
7 analysts
$7.00
7.77% Upside
 +10.5% ·
DXCM
Dexcom
 May 02, 2025 BUY Strong Buy
+26.2% avg upside
32 analysts
$100.00
20.51% Upside
 -24.8% ·
PEN
Penumbra
 Apr 24, 2025 BUY Buy
+1.9% avg upside
23 analysts
$318.00
2.14% Downside
 +10.6% ·
SENS
Senseonics Holdings
 Mar 04, 2025 BUY Buy
+190.2% avg upside
13 analysts
$50.00
870.92% Upside
 -51.1% ·
AHCO
AdaptHealth
 Feb 27, 2025 HOLD Strong Buy
+93.5% avg upside
13 analysts
$11.00
82.06% Upside
 -17.5% ·
CERS
Cerus
 Jan 13, 2025 BUY Strong Buy
+134.4% avg upside
10 analysts
$3.00
29.25% Upside
 +50.9% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mathew Blackman — Frequently Asked Questions
How accurate are Mathew Blackman's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Mathew's ratings were profitable over a one-year hold, with an average return of +2.9% per rating, or -4.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mathew ranked on 13Foresight?
Mathew Blackman is currently ranked #1450 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mathew cover?
Mathew most recently has ratings on PODD, ZBH, OFIX, ATEC, KIDS, SIBN, ISRG, SYK, GMED, TNDM, BBNX, CLPT and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.